The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the possibility that engineered immune therapies could reshape future treatment ...

Within this global landscape, the EXO 001 targeted exosome platform--developed jointly by CMUH and Ever Supreme Bio Technology--stands out for its use of high-biocompatibility, naturally derived ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body. These cells, ...

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as ...

A pioneering preclinical study has shown that CAR T cell therapy-a personalized form of immunotherapy used in cancer treatment-could be a highly effective tool against atherosclerosis, the condition ...

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...

A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body.